319 related articles for article (PubMed ID: 27206263)
21. Persistent Angiographic Abnormalities After Intravitreal Anti-Vascular Endothelial Growth Factor Therapy for Retinopathy of Prematurity.
Shah N; Gupta MP; Chan RVP
JAMA Ophthalmol; 2018 Apr; 136(4):436-437. PubMed ID: 29285531
[No Abstract] [Full Text] [Related]
22. Management of Retinopathy of Prematurity--Use of Anti-VEGF Therapy.
Tran KD; Cernichiaro-Espinosa LA; Berrocal AM
Asia Pac J Ophthalmol (Phila); 2018; 7(1):56-62. PubMed ID: 29376233
[TBL] [Abstract][Full Text] [Related]
23. Buckling surgery and supplemental intravitreal bevacizumab or photocoagulation on stage 4 retinopathy of prematurity eyes.
Futamura Y; Asami T; Nonobe N; Kachi S; Ito Y; Sato Y; Hayakawa M; Terasaki H
Jpn J Ophthalmol; 2015 Nov; 59(6):378-88. PubMed ID: 26265249
[TBL] [Abstract][Full Text] [Related]
24. Anti-Vascular Endothelial Growth Factor Therapy for Primary Treatment of Type 1 Retinopathy of Prematurity: A Report by the American Academy of Ophthalmology.
VanderVeen DK; Melia M; Yang MB; Hutchinson AK; Wilson LB; Lambert SR
Ophthalmology; 2017 May; 124(5):619-633. PubMed ID: 28341474
[TBL] [Abstract][Full Text] [Related]
25. Comparison of intravitreal ranibizumab and bevacizumab treatment for retinopathy of prematurity.
Erol MK; Coban DT; Sari ES; Bilgin AB; Dogan B; Ozdemir O; Tunay ZO
Arq Bras Oftalmol; 2015; 78(6):340-3. PubMed ID: 26677033
[TBL] [Abstract][Full Text] [Related]
26. The German ROP Registry: data from 90 infants treated for retinopathy of prematurity.
Walz JM; Bemme S; Pielen A; Aisenbrey S; Breuß H; Alex AF; Wagenfeld L; Schiedel S; Krohne TU; Stahl A;
Acta Ophthalmol; 2016 Dec; 94(8):e744-e752. PubMed ID: 27197876
[TBL] [Abstract][Full Text] [Related]
27. Current and future trends in treatment of severe retinopathy of prematurity.
Wallace DK; Wu KY
Clin Perinatol; 2013 Jun; 40(2):297-310. PubMed ID: 23719311
[TBL] [Abstract][Full Text] [Related]
28. Vascular endothelial growth factor plasma levels before and after treatment of retinopathy of prematurity with ranibizumab.
Zhou Y; Jiang Y; Bai Y; Wen J; Chen L
Graefes Arch Clin Exp Ophthalmol; 2016 Jan; 254(1):31-6. PubMed ID: 25851862
[TBL] [Abstract][Full Text] [Related]
29. PROGRESSIVE RETINAL DETACHMENT IN INFANTS WITH RETINOPATHY OF PREMATURITY TREATED WITH INTRAVITREAL BEVACIZUMAB OR RANIBIZUMAB.
Yonekawa Y; Wu WC; Nitulescu CE; Chan RVP; Thanos A; Thomas BJ; Todorich B; Drenser KA; Trese MT; Capone A
Retina; 2018 Jun; 38(6):1079-1083. PubMed ID: 28471890
[TBL] [Abstract][Full Text] [Related]
30. Role of VEGF Inhibition in the Treatment of Retinopathy of Prematurity.
Eldweik L; Mantagos IS
Semin Ophthalmol; 2016; 31(1-2):163-8. PubMed ID: 26959143
[TBL] [Abstract][Full Text] [Related]
31. Development of refractive error in children treated for retinopathy of prematurity with anti-vascular endothelial growth factor (anti-VEGF) agents: A meta-analysis and systematic review.
Tan QQ; Christiansen SP; Wang J
PLoS One; 2019; 14(12):e0225643. PubMed ID: 31790445
[TBL] [Abstract][Full Text] [Related]
32. Efficacy comparison of anti-vascular endothelial growth factor drugs for the treatment of type 1 retinopathy of prematurity: A network meta-analysis of randomised controlled trials.
Zhou M; Hashimoto K; Liu W; Cai Y; Liang J; Shi X; Zhao M
Graefes Arch Clin Exp Ophthalmol; 2024 May; 262(5):1409-1419. PubMed ID: 37815595
[TBL] [Abstract][Full Text] [Related]
33. Intravitreal ranibizumab monotherapy to treat retinopathy of prematurity zone II, stage 3 with plus disease.
Menke MN; Framme C; Nelle M; Berger MR; Sturm V; Wolf S
BMC Ophthalmol; 2015 Mar; 15():20. PubMed ID: 25886603
[TBL] [Abstract][Full Text] [Related]
34. Role of cytokines and treatment algorithms in retinopathy of prematurity.
Hartnett ME
Curr Opin Ophthalmol; 2017 May; 28(3):282-288. PubMed ID: 28141765
[TBL] [Abstract][Full Text] [Related]
35. Refractive Outcomes of 4-Year-old Children after Intravitreal Anti-vascular Endothelial Growth Factor versus Laser Photocoagulation for Retinopathy of Prematurity.
Kang HG; Kim TY; Han J; Han SH
Korean J Ophthalmol; 2019 Jun; 33(3):272-278. PubMed ID: 31179659
[TBL] [Abstract][Full Text] [Related]
36. An evidence-based meta-analysis of vascular endothelial growth factor inhibition in pediatric retinal diseases: part 1. Retinopathy of prematurity.
Mititelu M; Chaudhary KM; Lieberman RM
J Pediatr Ophthalmol Strabismus; 2012; 49(6):332-40. PubMed ID: 22938516
[TBL] [Abstract][Full Text] [Related]
37. Reactivation of retinopathy of prematurity six years after intravitreal injection of bevacizumab.
Yasin A; Sinha S; Smith R; Jain SF; Hejkal T; Rychwalski P
J AAPOS; 2023 Aug; 27(4):236-239. PubMed ID: 37451499
[TBL] [Abstract][Full Text] [Related]
38. Intravitreal bevacizumab for retinopathy of prematurity: Considerations for informed consent.
Mireskandari K; Collins ME; Tehrani N
Can J Ophthalmol; 2015 Dec; 50(6):409-12. PubMed ID: 26651298
[No Abstract] [Full Text] [Related]
39. Refractive outcomes following the treatment of retinopathy of prematurity in the anti-VEGF era: a literature review.
Abri Aghdam K; Khadamy J; Falavarjani KG; Tsui I
J AAPOS; 2016 Dec; 20(6):539-540.e3. PubMed ID: 27810419
[TBL] [Abstract][Full Text] [Related]
40. [VEGF antibodies as therapy for retinopathy of prematurity].
Oberacher-Velten IM; Helbig H
Klin Monbl Augenheilkd; 2010 Sep; 227(9):694-700. PubMed ID: 20845249
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
